The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Ocular Therapeutix launched a Phase II trial of its punctum plugs, a possible eye-drop killer for patients with glaucoma or ocular hypertension.
The company’s travoprost-releasing punctum plug, designed to fit into the entry of the tear duct, releases drug therapy to the surface of the eye over several months.
Consumer Union demanded that a new user fee deal the medical device industry brokered with the FDA include more stringent oversight of med-tech makers.
"We shouldn’t be used as guinea pigs when it comes to something as serious as a medical implant," according to the organization’s website. "Medical devices should not be ticking time bombs!"
Here’s a roundup of the latest dealflow and investment news:
Ocular Therapeutix Inc. added $6 million to its Series C round.
The equity and options-based round was supported by 29 investors on aggregate, according to a Securities & Exchange Commission filing.
Amar Sawhney has a knack for turning gel into gold.
Over the years, the serial entrepreneur managed to leverage his work in hydrogel technology at the University of Texas into the basis for six companies, including one snapped up by Genzyme early in the decade and another that Covidien predecessor Tyco Healthcare acquired in 2006.
